Combination treatment for leukemia that stopped responding to standard therapy
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination of three drugs (gilteritinib, azacitidine, and venetoclax) for people with acute myeloid leukemia (AML) that no longer responds to azacitidine and venetoclax. The goal is to see if this triple therapy can help achieve remission and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of AML that did not respond to or came back after treatment with azacitidine and venetoclax.
- You do not have FLT3 gene mutations (both ITD and TKD types) based on recent tests.
- You are generally able to perform daily activities (ECOG performance status 0-2).
- You are willing to use effective birth control during and for 6 months after treatment, if applicable.
- You are not pregnant or breastfeeding and agree to avoid pregnancy during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests a combination of medicines (ASTX727, venetoclax, and gilteritinib) for adults with FLT3-mutated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to see how well the treatment works and how safe it is for people whose disease has come back, is not responding, or (for some) is newly diagnosed.
This trial tests a combination of three drugs (bugitinib, venetoclax, and cytarabine) for patients with acute myeloid leukemia (AML) that has returned or didn't respond to prior treatments. The goal is to see if this combination can help patients achieve remission and improve survival.
This trial tests a combination of three drugs—daunorubicin, cytarabine, and venetoclax—for people with newly diagnosed AML who are strong enough to receive intensive chemotherapy. The goal is to see if adding venetoclax helps improve treatment outcomes.
This trial tests a new combination of chemotherapy (FLAI) and a targeted drug (Gilteritinib) for adults with acute myeloid leukemia (AML) that has a specific genetic change called FLT3. It aims to see if the combo works better than standard treatment.
This trial tests adding a targeted drug called gilteritinib to a standard two-drug combination (venetoclax and azacitidine) for people with a specific genetic change (FLT3 mutation) in their acute myeloid leukemia (AML). The goal is to see if the three drugs together work better than the two alone, for patients who cannot tolerate strong chemotherapy.
This trial is testing a three-drug combination for people newly diagnosed with a type of AML that has a FLT3 mutation. The goal is to see if this treatment works better than standard care.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.